Thirty Years of LAM Research Raised Less Than One Year of the Market It Created

Two numbers that should not sit this close together

The LAM Foundation was founded in 1995 as a grassroots effort by patients and families. In thirty years it has raised more than USD 38 million, directed more than USD 19 million of that into research, and — by its own estimate — levered a further USD 90 million from other sources. Add those last two together and you get USD 109 million of cumulative research capital behind lymphangioleiomyomatosis.

The market that research produced is worth USD 142.8 million a year, on Pheonix Research’s sizing of the global LAM therapeutics market.

Read those two figures in sequence. Thirty years of global investment in understanding and treating this disease is smaller than a single year of the revenue that investment created. The ratio is 0.76 to one. No other category in the report’s coverage behaves this way, and once you have done that division, the empty pipeline stops looking like neglect and starts looking like an equilibrium.

What the money actually bought

It is worth being precise about how much was spent, because the temptation with rare disease is to assume the sums are large and the returns merely slow. They are not large. Spread across those thirty years, the foundation’s research spend averages USD 633,333 a year. That is 0.44 per cent of the annual market value it produced.

What it bought is not nothing. The foundation attributes to its grants both the diagnostic biomarker that can spare a patient a lung biopsy and the investigator-initiated groundwork behind the trial that produced the only approved treatment. That is an unusually high return on a small budget — one of the better philanthropic yields in respiratory medicine. The point is not that the money was wasted. The point is that this is all the money there is.

The largest single public line touching the disease is not about LAM at all. The Department of Defense Tuberous Sclerosis Complex Research Program records USD 121 million appropriated across FY2002–06 and FY2008–24, 228 awards, and USD 10 million appropriated for FY2026. Across twenty-two funded fiscal years that is roughly USD 5.5 million a year — 8.68 times the LAM Foundation’s average annual research spend.

That disparity is not an argument against the TSCRP. It is the explanation for a pattern you can see throughout the disease literature: TSC-associated LAM, which is 62 per cent of the treated population in the report’s build, is considerably better characterised than the sporadic form. The reason is not that one is more interesting. The reason is that one has a congressional appropriation behind it and the other has bake sales.

The one transaction, and the price nobody disclosed

In twelve years there has been exactly one commercial transaction of consequence in LAM, and if you go looking for its terms you will not find them. Nobelpharma concluded a licensing agreement with Pfizer for Japanese rights to sirolimus on 1 June 2012. Orphan designation followed on 13 September 2012, the application on 21 October 2013, approval on 4 July 2014. The consideration was not disclosed then and has not been disclosed since.

What was disclosed is the obligation, and it is more informative than a headline number would have been. The approval carried a ten-year re-examination period, a drug use-results survey, and all-case post-marketing surveillance — imposed, in the regulator’s own reasoning, because the product had been evaluated in an extremely limited number of patients. All-case surveillance is not a filing fee. It is a multi-year, company-funded data collection programme running over every patient in the country. The acquirer paid twice: once, invisibly, for the licence, and again, visibly, for the evidence.

Now look at the corporate form rather than the deal terms. The only company that has ever taken a LAM drug to market is a Japanese specialist in neglected medicines founded in 2003, whose stated purpose is to supply exactly the products other companies do not pursue. It is not a venture-backed developer chasing an orphan return, because a company with a return target would have read the price table and declined — which is what most of the orphan commercialisation field does with assets of this size, and what Novartis effectively did in 2012, having run the only company-sponsored LAM trial and never filing for the indication.

The trial that costs less than the thing it decides

Here is the objection, and it is a fair one: surely a trial is simply too expensive for a disease this rare. Test it against the numbers.

MILED, NCT03150914, randomised sixty patients with preserved lung function to 1 mg daily sirolimus or placebo for two years. Primary endpoint: FEV1 slope. Led by the University of Cincinnati, with the NHLBI, NCATS and the LAM Foundation as collaborators, and the University of South Florida coordinating data. Its primary completion date, 30 June 2025, has passed. The registry reads active, not recruiting. No result has been published.

Cost the drug at the blended spend the market model implies — USD 6,348 per patient-year. Sixty patients, two years: USD 761,760. That is 0.53 per cent of one year of the market the trial will determine. If the barrier to entry in LAM were the cost of running a trial, a commercial sponsor would have taken MILED years ago. None did.

The reason is on the next line. A positive MILED moves the treatment threshold and brings in patients with preserved lung function. It expands the treated population. It does not touch the price, which is USD 7.0032 per milligram whether the patient is early or late, mild or severe. Volume at a generic price is not a return. The trial is cheap and still unfundable, and those two facts are consistent with each other.

What a LAM asset is worth, when anything is

Two exits in the same broad patient population have been priced in public markets inside four years, and between them they bracket the question.

With a label. UCB completed its acquisition of Zogenix on 7 March 2022 at USD 26.00 per share plus a USD 2.00 contingent value right, a total transaction value of up to approximately USD 1.9 billion, for a company with two labelled orphan epilepsy indications and a pipeline.

After a miss. Marinus announced on 24 October 2024 that TrustTSC, its phase 3 trial of ganaxolone in tuberous sclerosis complex — 129 patients, the same clinics and the same families that supply LAM — had missed, with median 28-day seizure reduction of 19.7 per cent against 10.2 per cent on placebo, p=0.09. Immedica completed its acquisition of Marinus on 11 February 2025 at USD 0.55 per share.

LAM sits in neither position. It has no label of its own to sell and no failed pivotal trial to explain. Between USD 1.9 billion and fifty-five cents there is an entire range in which a LAM asset would sit if a LAM asset existed — and none does, because there is nothing to own. The molecule is generic. The price is set by the authorised generic. What a buyer would acquire is a sales obligation without an asset.

The four events that would change it

None of this is a prediction that LAM stays frozen. It is a statement about which levers exist.

• A positive MILED readout. Expands the treated population. Necessary for the base case, and not sufficient for capital to arrive, for the reason above.
• A reimbursement decision for nintedanib in LAM. The only live price event in the category: more than USD 110,000 a year against USD 5,112 for generic sirolimus at 2 mg. Worth more to the value curve than any clinical data in the pipeline, and it rests on prescriber behaviour rather than on a trial result.
• An immune-mechanism asset reaching IND. Midkine or B7-H3 blockade, or GD3-directed cell therapy — the only route to a disease-modifying claim, and therefore to pricing that is not a generic reference. The cell-therapy economics that make this plausible are years from being applied to a lung disease with no sponsor. Today the thread is unsponsored.
• European generic labelling. Once orphan market exclusivity expires, a generic can hold the LAM indication in its own right. That removes the last pricing argument for a branded product and completes the transition to generic reference pricing — good for patients, and a further cut to value per treated patient.

Three of those four are pricing events. Only one is a scientific one, and it is the one the field keeps waiting for.

The uncomfortable conclusion

It would be satisfying to end with the observation that LAM is neglected because it is rare, or because it affects women, or because the biology defeated everyone. The evidence supports none of those. The target — mTOR — is one of the best-characterised in medicine, and the drug that hits it works. What defeated the field is arithmetic: a generic molecule in a small population, at a price that cannot carry a trial, let alone a launch.

The companies that might have changed that are not villains in this story. They did the rational thing. Novartis ran a trial, saw the price, and did not file. Boehringer Ingelheim’s nintedanib study produced a signal in an uncontrolled design and no filing followed. What filled the gap was a patient foundation, a defence appropriation, and one specialist licensee willing to accept an all-case surveillance obligation as the cost of a label.

That is the equilibrium, and the report’s forecast is a forecast that it holds. Anyone reading this as an investment thesis should be clear about what they are buying: not an underserved market waiting for a sponsor, but a market whose price is set by a reference product and whose evidence is set by philanthropy. The question for the next decade is not who will fund the next LAM trial. It is whether any event exists that would make the next trial fundable by someone who needs a return. On the evidence, there is exactly one, and it is a reimbursement decision in a disease area the orphan pricing system was designed for rather than a scientific one.

This article draws on the Global Lymphangioleiomyomatosis Therapeutics Market Report, Size, Share and Forecast 2026–2033. For the trial-design history behind the single approval, see The LAM Pipeline Runs on Borrowed Placebos.